[1] Conf Retroviruses Opportunistic Infect - 10th, 2003. Abstract 553. [2] FDA - Prezista Approval Letter. Available at: http://www.fda.gov/cder/foi/appletter/2006/021976s000LTR.pdf. Accessed 08/30/07. [3] Tibotec - Prezista Prescribing Information, October 2006, p. 8. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [4] HIV and Hepatitis.com - Conference Coverage: 4th IAS Conference on Pathogenesis, Treatment, and Prevention (July 2007)-48-week Efficacy and Safety of Darunavir (Prezista) Boosted with Ritonavir versus Lopinavir/ritonavir (Kaletra) in Treatment-experienced HIV Patients: The TITAN Trial. Available at: http://www.hivandhepatitis.com/2007icr/ias/docs/072707_b.html. Accessed 08/30/07. [5] Interscience Conf on Antimicrobial Agents and Chemotherapy - 47th, 2007. Abstract H-718B. Available at: http://www.icaac.org/accepted-abstracts.asp. Accessed 11/21/07. [6] FDA - HIV/AIDS Update - Important information about Prezista (darunavir). Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed on: 10/22/08.
[7] Conf Retroviruses Opportunistic Infect - 10th, 2003. Abstract 553. [8] Tibotec - Prezista Prescribing Information, October 2006, p. 8. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [9] Tibotec - HIV: EAP. Available at: http://www.tibotec.com/bgdisplay.jhtml?itemname=EAP2. Accessed 08/30/07. [10] Tibotec - Prezista Prescribing Information, October 2006, p. 22. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [11] Tibotec - Prezista Prescribing Information, October 2006, p. 22. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [12] FDA - HIV/AIDS Update - Important information about Prezista (darunavir). Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed on: 10/22/08.
[13] Tibotec - Prezista Prescribing Information, October 2008, p. 22. Available at: http://www.prezista.com/prescribing_information.html. Accessed 10/28/08. [14] FDA - HIV/AIDS Update - Important information about Prezista (darunavir). Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed on: 10/22/08.
[15] Tibotec - Prezista Prescribing Information, October 2006, p. 15. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [16] Tibotec - Prezista Prescribing Information, October 2006, p. 22. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [17] Tibotec - Prezista Prescribing Information, October 2006, p. 1. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [18] Tibotec - - HIV: Prezista. Available at: http://www.tibotec.com/bgdisplay.jhtml?itemname=HIV_tmc114. Accessed 08/30/07. [19] Tibotec - Prezista Prescribing Information, October 2006, pp. 2,4. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [20] Tibotec - Prezista Prescribing Information, October 2006, p. 10. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [21] Tibotec - Prezista Prescribing Information, October 2006, p. 5. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [22] Tibotec - Prezista Prescribing Information, October 2006, pp. 5-6. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [23] Conf Retroviruses Opportunistic Infect - 10th, 2003. Abstract 549. [24] Conf Retroviruses Opportunistic Infect - 10th, 2003. Abstract 8. [25] Conf Retroviruses Opportunistic Infect - 10th, 2003. Abstract 549. [26] Tibotec - Prezista Prescribing Information, October 2006, p. 19. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [27] FDA - HIV/AIDS Update - Important information about Prezista (darunavir). Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed on: 10/22/08.
[28] Tibotec - Prezista Prescribing Information, October 2006, p. 19. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [29] Tibotec - Prezista Prescribing Information, October 2006, p. 5. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [30] Tibotec - Prezista Prescribing Information, October 2006, p. 6. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [31] Tibotec - Prezista Prescribing Information, October 2006, p. 6. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [32] Tibotec - Prezista Prescribing Information, October 2006, pp. 2-3. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [33] HIV and Hepatitis.com - Efficacy and Safety of Darunavir/ritonavir at Week 48 in Treatment-experienced HIV Patients: Pooled Analysis of POWER 1 and 2 Trials. Available at: http://www.hivandhepatitis.com/recent/2007/040607_e.html. Accessed 08/30/07. [34] HIV and Hepatitis.com - Conference Coverage: 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention (July 2007)-48-week Efficacy and Safety of Darunavir (Prezista) Boosted with Ritonavir versus Lopinavir/ritonavir (Kaletra) in Treatment-experienced HIV Patients: The TITAN Trial. Available at: http://www.hivandhepatitis.com/2007icr/ias/docs/072707_b.html. Accessed 08/30/07. [35] Interscience Conf on Antimicrobial Agents and Chemotherapy - 47th, 2007. Abstract H-718B. Available at: http://www.icaac.org/accepted-abstracts.asp. Accessed 11/21/07. [36] Interscience Conf on Antimicrobial Agents and Chemotherapy - 48th, 2008. Abstract H-1250c. [37] AIDS Clin Care - Volume 1; August 11, 2008. [38] Medical News Today - Phase III Study In Treatment-naive Adults With HIV Evaluates Efficacy And Safety Of Once Daily Prezista/ritonavir versus Kaletra/ritonavir [article], September 20, 2007. Available at: http://www.medicalnewstoday.com/articles/82981.php. Accessed 11/23/08. [39] AIDS Read - 2007;17:194-8, 201 [40] Tibotec - Prezista Prescribing Information, October 2006, pp. 1-2. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [41] Tibotec - Prezista Prescribing Information, October 2006, pp. 2-3. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [42] Tibotec - Prezista Prescribing Information, October 2006, p. 2. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [43] Tibotec - Prezista Prescribing Information, October 2006, p. 2. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [44] Tibotec - Prezista Prescribing Information, October 2006, p. 20. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [45] Tibotec - Prezista Prescribing Information, October 2006, p. 22. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [46] Interscience Conf on Antimicrobial Agents and Chemotherapy - 47th, 2007. Abstract H-718B. Available at: http://www.icaac.org/accepted-abstracts.asp. Accessed 11/21/07. [47] Tibotec - Prezista Prescribing Information, October 2006, p. 14. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [48] Tibotec - Prezista Prescribing Information, February 2008, p. 21. Available at: http://www.tibotectherapeutics.com/tibotectherapeutics/documents/us_package_insert.pdf. Accessed 03/12/08. [49] FDA - Medwatch: Prezista (darunavir), March 12, 2008. Available at: http://www.fda.gov/medwatch/safety/2008/safety08.htm#Prezista. Accessed 03/12/08. [50] Tibotec - Prezista Dear Health Care Professional letter, March 2008. Available at: http://www.tibotectherapeutics.com/tibotectherapeutics/documents/dhcpletter.pdf. Accessed 03/12/08. [51] Tibotec - Prezista Prescribing Information, October 2006, p. 14. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [52] Tibotec - Prezista Prescribing Information, October 2006, p. 14. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [53] Tibotec - Prezista Prescribing Information, October 2006, p. 14. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [54] Conf Retroviruses Opportunistic Infect - 11th, 2004. Abstract 164LB. [55] Natap.org - Conference Reports: TMC114/r is well tolerated in 3-class-experienced patients: Week 24 primary safety analysis of POWER 1 (TMC114-C213). Available at: http://www.natap.org/2005/ias/ias_15.htm. Accessed 08/30/07. [56] Aidsmap.com - News: After 48 weeks of study and 24 weeks in the real world, darunavir continues to show staying power, December 12, 2006. Available at: http://www.aidsmap.com. Accessed 08/30/07. [57] AIDS Read - 2007;17:194-8, 201 [58] FDA - HIV/AIDS Update - Important information about Prezista (darunavir). Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed on: 10/22/08.
[59] Tibotec - Prezista Prescribing Information, October 2006, p. 15. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [60] Tibotec - Prezista Prescribing Information, October 2006, p. 17. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [61] Tibotec - Prezista Prescribing Information, October 2006, p. 17. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [62] Tibotec - Prezista Prescribing Information, October 2006, p. 17. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [63] Tibotec - Prezista Prescribing Information, October 2006, p. 17. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [64] Tibotec - Prezista Prescribing Information, October 2006, p. 4. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [65] Tibotec - Prezista Prescribing Information, October 2006, p. 4. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [66] FDA - HIV/AIDS Update - Important information about Prezista (darunavir). Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed on: 10/22/08.
[67] Tibotec - Prezista Prescribing Information, October 2006, p. 18. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [68] Tibotec - Prezista Prescribing Information, October 2006, p. 18. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [69] FDA - HIV/AIDS Update - Important information about Prezista (darunavir). Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed on: 10/22/08.
[70] Tibotec - Prezista Prescribing Information, October 2006, p. 17. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [71] Tibotec - Prezista Prescribing Information, October 2006, p. 17. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [72] Tibotec - Prezista Prescribing Information, October 2006, p. 17. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [73] Tibotec - Prezista Prescribing Information, October 2006, p. 17. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [74] Tibotec - Prezista Prescribing Information, October 2006, p. 17. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [75] Tibotec - Prezista Prescribing Information, October 2006, p. 17. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [76] Tibotec - Prezista Prescribing Information, October 2006, p. 17. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [77] FDA - HIV/AIDS Update - Important information about Prezista (darunavir). Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed on: 10/22/08.
[78] Tibotec - Prezista Prescribing Information, October 2006, p. 17. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [79] Tibotec - Prezista Prescribing Information, October 2006, p. 18. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [80] Tibotec - Prezista Prescribing Information, October 2006, p. 18. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [81] Tibotec - Prezista Prescribing Information, October 2006, p. 18. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [82] Tibotec - Prezista Prescribing Information, October 2006, p. 18. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [83] Tibotec - Prezista Prescribing Information, October 2006, p. 18. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [84] International HIV Drug Resistance Workshop - 8th, 2007. Abstract 55. [85] Tibotec - Prezista Prescribing Information, October 2006, p. 15. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [86] Tibotec - Prezista Prescribing Information, October 2006, p. 16. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [87] Interscience Conf on Antimicrobial Agents and Chemotherapy - 47th, 2007. Abstract H-718B. Available at: http://www.icaac.org/accepted-abstracts.asp. Accessed 11/21/07. [88] ChemIDplus - Available at: http://chem.sis.nlm.nih.gov/chemidplus/chemidlite.jsp. Accessed 08/30/07. [89] ChemIDplus - Available at: http://chem.sis.nlm.nih.gov/chemidplus/chemidlite.jsp. Accessed 08/30/07. [90] ChemIDplus - Available at: http://chem.sis.nlm.nih.gov/chemidplus/chemidlite.jsp. Accessed 08/30/07. [91] Calculation. - [92] Tibotec - Prezista Prescribing Information, October 2006, p. 1. Available at: http://www.prezista.com. Accessed 08/30/07. [93] Tibotec - Prezista Prescribing Information, October 2006, p. 1. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [94] Tibotec - Prezista Prescribing Information, October 2006, p. 1. Available at: http://www.prezista.com/prescribing_information.html. Accessed 08/30/07. [95] ChemIDplus - Available at: http://chem.sis.nlm.nih.gov/chemidplus/chemidlite.jsp. Accessed 08/30/07.
|